Short Interest in Clearmind Medicine Inc. (NASDAQ:CMND) Drops By 16.0%

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 274,600 shares, a decrease of 16.0% from the January 31st total of 326,800 shares. Approximately 9.2% of the company’s shares are short sold. Based on an average daily trading volume, of 955,100 shares, the short-interest ratio is presently 0.3 days.

Clearmind Medicine Trading Down 3.4 %

CMND stock traded down $0.04 during midday trading on Thursday, reaching $1.12. The company’s stock had a trading volume of 25,527 shares, compared to its average volume of 1,069,485. The business’s 50-day simple moving average is $1.40 and its 200-day simple moving average is $1.37. The stock has a market cap of $4.78 million, a PE ratio of -0.60 and a beta of 1.04. Clearmind Medicine has a 52 week low of $0.95 and a 52 week high of $2.30. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 0.01.

Clearmind Medicine (NASDAQ:CMND) last released its quarterly earnings data on Wednesday, January 22nd. The company reported ($0.11) EPS for the quarter.

Institutional Trading of Clearmind Medicine

An institutional investor recently bought a new position in Clearmind Medicine stock. Virtu Financial LLC bought a new stake in Clearmind Medicine Inc. (NASDAQ:CMND) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 39,479 shares of the company’s stock, valued at approximately $54,000. Virtu Financial LLC owned approximately 0.92% of Clearmind Medicine as of its most recent filing with the Securities and Exchange Commission (SEC). 96.05% of the stock is currently owned by hedge funds and other institutional investors.

Clearmind Medicine Company Profile

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.